Health-Related Quality of Life and Financial Burden in Ethiopian Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors: A Cross-Sectional Study
Our results indicate that the HRQoL profile of patients with CML living in Ethiopia may be worse across several important functional and symptom domains than that of their peers living in an HIC. In addition, FT is highly prevalent among these patients and it is associated with poorer HRQoL outcomes.
Authors
- Atalay Mulu Fentie (ORCID: https://orcid.org/0000-0001-6065-0695)
- Fabio Efficace (ORCID: https://orcid.org/0000-0002-5065-5166)
- Getahun Asres
- Marta Cipriani (ORCID: https://orcid.org/0000-0001-6159-8059)
- Alfonso Piciocchi (ORCID: https://orcid.org/0000-0001-8648-885X)
- Lalise Gemechu
- Amha Gebremedhin (ORCID: https://orcid.org/0000-0003-3010-2860)
- Fisihatsion Tadesse (ORCID: https://orcid.org/0000-0003-4270-9424)
- Francesco Sparano (ORCID: https://orcid.org/0000-0002-1358-3095)
- Daniela Krepper (ORCID: https://orcid.org/0009-0009-0026-9548)
- Abdulaziz Abubeker
Institutions
- Universität Innsbruck (AT)
- Fondazione Gimema Onlus (IT)
- University Hospital Innsbruck (AT)
- Addis Ababa University (ET)
- Sapienza University of Rome (IT)
- University of Gondar (ET)
Publication Details
- Journal
- JCO Global Oncology
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1200/go-24-00281
- Citations
- 2
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.91